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esidual Pulmonary Artery
ypertension After
itral Valve Replacement
ize Matters!*
red A. Crawford, JR, MD
harleston, South Carolina
t has been previously observed that the rate and extent of
egression of preoperative pulmonary artery hypertension is
ighly variable after mitral valve surgery and that residual
ulmonary artery hypertension may be a risk factor for poor
utcomes after surgery. In this issue of the Journal, Li et al.
1) hypothesized that valve prosthesis-patient mismatch
PPM) might be an important factor in preventing the
egression of pulmonary artery hypertension after mitral
alve replacement (MVR). They retrospectively analyzed
ata from 56 patients who had previously undergone MVR
nd who were evaluated by Doppler echocardiography at
arying time intervals postoperatively. Patients with pros-
hetic valve dysfunction and significant aortic valve disease
ere excluded, but no mention was made of the status of left
entricular function pre- or postoperatively in the study
atients. Patient-prosthesis mismatch was defined as in-
See page 1034
exed effective orifice area (EOA) 1.2 cm2/m2 and pul-
onary artery hypertension as systolic pulmonary artery
ressure 40 mm Hg. Many different types of prosthetic
alves (overall 84% mechanical, 16% tissue) were utilized,
nd prosthetic valve selection criteria were not defined. The
uthors found that average postoperative systolic pulmonary
rtery pressure was significantly higher in patients with
PM compared to patients with no PPM (46  8 mm Hg
s. 34  8 mm Hg; p  0.001), and that the prevalence of
ersistent pulmonary artery hypertension after MVR was
reater in patients with PPM than in those with no PPM
68% vs. 19%). The indexed EOA was by far the strongest
redictor of systolic pulmonary artery pressure. They con-
luded that PPM can best be prevented by implanting the
argest possible prosthesis with the greatest EOA and
ecommended that a “simple” prospective strategy of utiliz-
ng the largest bileaflet mechanical mitral valve prosthesis
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Surgery, Medical University of South Carolina,
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ducation program sponsored by St. Jude Medical for the past several years and owns
tock in Medtronic Corporation.ight be most effective in avoiding PPM and residual
ostoperative pulmonary artery hypertension.
A relatively large body of information has been developed
egarding PPM after aortic valve replacement. Various
tudies have suggested that aortic PPM resulting in a
esidual transprosthetic gradient might be associated with
lower and less regression of left ventricular hypertrophy
ostoperatively. Some studies have indicated that incom-
lete regression of left ventricular hypertrophy is related to
ore postoperative cardiac events and poorer long-term
urvival (2) while others have suggested that it is of less
mportance (3,4). Much less data has accumulated regarding
PM after MVR. The original patient reported by Rahim-
oola and Murphy (5) may in fact not represent mitral PPM
t all.
While the findings in this study are interesting, there are
ignificant limitations, some of which are acknowledged by
he authors. The study is retrospective, and while the study
atients are “consecutive” in regards to evaluation of patients
resenting to the clinic for follow-up, it did not represent a
onsecutive contemporary series of patients undergoing
VR. The patients were evaluated at intervals ranging from
to 102 months postoperatively, and, in fact, there was a
ignificant correlation between the time to follow-up and
ostoperative pulmonary artery pressure by univariate anal-
sis. The study would be stronger if follow-up intervals
time of evaluation) were similar in all patients because
ulmonary artery hypertension does not always regress
mmediately after operation. Despite the known correlation
etween pulmonary artery pressure obtained by Doppler
chocardiography and that obtained by catheterization, it
ould have been nice to have the Doppler data confirmed
y catheterization (at least in some patients) and pulmonary
ascular resistance measured because increased pulmonary
ascular resistance may be an independent cause of residual
ulmonary artery hypertension despite satisfactory relief of
itral stenosis or mitral regurgitation by surgery.
Several things about this study stand out immediately, or
t least to the surgeon. One is the large number (52%) of
elatively small prostheses (size 25 and 27) that were
tilized. It should not be too surprising, therefore, that a
ignificant number of patients in the series had residual
ulmonary artery hypertension given the fact that the
ajority had small prosthetic valves utilized. While many
ifferent types of prosthetic valves were utilized in this
tudy, it is well known that size 25 and 27 prostheses may be
ssociated with residual gradients due to relatively small
OA. When prosthetic valves of this size are utilized in
dult patients, especially those with 1.8 m2 body surface
rea, one is, in effect, replacing a stenotic mitral valve with
stenotic prosthetic valve, and residual pulmonary artery
ypertension should be expected rather than surprising. In
ur most recent 100 consecutive adult patients undergoing
VR (all types of prostheses), only 35% required mitralalve prostheses of size 27 or less compared to the 52% in
t
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Editorial Comment April 5, 2005:1041–2his series. In a recent follow-up of all patients undergoing
VR with only St. Jude Medical prostheses (used in 67% of
he patients in the Li et al. [1] study), only 16% were size 25
r 27 (6). The manuscript does not provide selection criteria
or valve type nor does it explain why such small valves were
tilized in so many patients. This does, however, probably
xplain the unexpectedly high rate of residual pulmonary
ypertension, and, accordingly, their recommendation to
tilize the largest possible mitral valve prosthesis (within
eason) is appropriate.
A second surprising finding is that the chordal apparatus
as preserved in only 41% of the patients in this series.
nless an extremely high percentage of the patients had
nderlying rheumatic disease, one would expect the per-
entage of chordal preservation (either total or partial) to
pproach 100% given the knowledge that failure to do so
ay be a cause of postoperative left ventricular dysfunction.
n fact, no real mention is made of either pre- or postop-
rative left ventricular function, and left ventricular dysfunc-
ion of any type could play a role in residual pulmonary
rtery hypertension.
The final thing that stands out is the very high rate of
tilization of mechanical prostheses (84%), especially in a
atient population with a mean age of 65 years. Currently,
he trend is toward a greater utilization of tissue valves as
pposed to mechanical valves, and in our most recent 100
VRs, only 28% received mechanical prostheses (compared
o 84% in this series). In addition, the authors go on to
ecommend that PPM and residual pulmonary artery hy-
ertension might be prevented by utilization of the largest
ileaflet mechanical valve prosthesis in all patients because
f the superior hemodynamics associated with these valves.
n their series, there was no difference in the rate of
tilization of mechanical valves in patients with PPM (88%)
ersus those without PPM (83%). Because 84% of the
atients in the entire series received mechanical valves, only
n additional 16% could have possibly benefitted from their
ecommendation, and far more than that had residual
ulmonary hypertension. Mechanical valves require long-
erm anticoagulation and are clearly contraindicated in
atients with bleeding disorders, in most elderly patients,
nd women of childbearing age, as well as in some other
atients. Thus, the authors’ recommendations for more
idespread utilization of mechanical bileaflet valves are
imply not an option for all patients despite possible
emodynamic advantages.
The authors have made an important observation thatesidual pulmonary hypertension after MVR is possiblyelated to PPM. However, they have not shown that this
elatively mild degree of residual pulmonary hypertension
as a significant effect on long-term survival or functional
apacity. Nevertheless, all cardiothoracic surgeons should be
ware of the implications of their observation and should
ttempt to implant the largest prosthesis that fits comfort-
bly at the time of MVR. However, no attempt should be
ade to “oversize” the valve, as this could lead to potential
omplications.
Perhaps, most importantly, the authors’ observation in-
irectly reinforces the superiority of mitral valve repair over
VR with any size or type of prosthesis because of the
ell-documented improved hemodynamics, decreased rate
f thromboembolism, and superiority of long-term out-
omes associated with mitral valve repair (7,8). Mitral valve
epair as opposed to replacement in as many patients as
ossible would perhaps be the most important recommen-
ation of this study in order to avoid PPM and residual
ulmonary artery hypertension. In order to document this
ypothesis, it would be interesting to repeat the study in a
eries of patients who have undergone mitral valve repair (as
pposed to replacement) in order to compare the rates of
esidual pulmonary hypertension.
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epartment of Surgery, Medical University of South Carolina, 96
onathan Lucas Street, Room 409, Charleston, South Carolina
9425. E-mail: crawfrdf@musc.edu.
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